Does the media favor ACRS or DTIL?

In the previous week, Aclaris Therapeutics had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 13 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 0.41 beat Aclaris Therapeutics' score of 0.07 indicating that Precision BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precision BioSciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer CLYM or DTIL?

In the previous week, Precision BioSciences had 3 more articles in the media than Climb Bio. MarketBeat recorded 13 mentions for Precision BioSciences and 10 mentions for Climb Bio. Climb Bio's average media sentiment score of 0.73 beat Precision BioSciences' score of 0.41 indicating that Climb Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precision BioSciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor DTIL or DRUG?

In the previous week, Precision BioSciences had 9 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 13 mentions for Precision BioSciences and 4 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.97 beat Precision BioSciences' score of 0.41 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precision BioSciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Bright Minds Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CADL or DTIL?

In the previous week, Candel Therapeutics had 6 more articles in the media than Precision BioSciences. MarketBeat recorded 19 mentions for Candel Therapeutics and 13 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 0.41 beat Candel Therapeutics' score of -0.02 indicating that Precision BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 2 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Precision BioSciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to DTIL or RIGL?

In the previous week, Precision BioSciences had 7 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 13 mentions for Precision BioSciences and 6 mentions for Rigel Pharmaceuticals. Precision BioSciences' average media sentiment score of 0.41 beat Rigel Pharmaceuticals' score of 0.38 indicating that Precision BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precision BioSciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Rigel Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Precision BioSciences (DTIL) Competitors

$7.43 +0.13 (+1.78%)

Closing price 04:00 PM Eastern

Extended Trading

$7.44 +0.02 (+0.20%)

As of 07:34 PM Eastern

Compare

DTIL vs. ACRS, CLYM, DRUG, CADL, and RIGL

Should you buy Precision BioSciences stock or one of its competitors? Precision BioSciences's main competitors and comparable companies include Aclaris Therapeutics (ACRS), Climb Bio (CLYM), Bright Minds Biosciences (DRUG), Candel Therapeutics (CADL), and Rigel Pharmaceuticals (RIGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Precision BioSciences compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Precision BioSciences (NASDAQ:DTIL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Precision BioSciences has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	103.21	-$64.92M	-$0.58	N/A
Precision BioSciences	$34.26M	5.99	-$45.72M	-$2.80	N/A

Aclaris Therapeutics currently has a consensus price target of $11.50, suggesting a potential upside of 98.96%. Precision BioSciences has a consensus price target of $32.25, suggesting a potential upside of 334.05%. Given Precision BioSciences' higher possible upside, analysts plainly believe Precision BioSciences is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Aclaris Therapeutics had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 13 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 0.41 beat Aclaris Therapeutics' score of 0.07 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precision BioSciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Aclaris Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

Precision BioSciences has a net margin of -96.73% compared to Aclaris Therapeutics' net margin of -921.50%. Aclaris Therapeutics' return on equity of -61.65% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
Precision BioSciences	-96.73%	-72.52%	-32.25%

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by insiders. Comparatively, 2.7% of Precision BioSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Aclaris Therapeutics and Precision BioSciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Precision BioSciences compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and Precision BioSciences (NASDAQ:DTIL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Precision BioSciences has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A
Precision BioSciences	$34.26M	5.99	-$45.72M	-$2.80	N/A

Climb Bio currently has a consensus target price of $22.75, indicating a potential upside of 39.31%. Precision BioSciences has a consensus target price of $32.25, indicating a potential upside of 334.05%. Given Precision BioSciences' higher probable upside, analysts plainly believe Precision BioSciences is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Climb Bio has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

Climb Bio has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Climb Bio's return on equity of -31.79% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.79%	-30.79%
Precision BioSciences	-96.73%	-72.52%	-32.25%

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by company insiders. Comparatively, 2.7% of Precision BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Precision BioSciences had 3 more articles in the media than Climb Bio. MarketBeat recorded 13 mentions for Precision BioSciences and 10 mentions for Climb Bio. Climb Bio's average media sentiment score of 0.73 beat Precision BioSciences' score of 0.41 indicating that Climb Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precision BioSciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Climb Bio beats Precision BioSciences on 9 of the 16 factors compared between the two stocks.

How does Precision BioSciences compare to Bright Minds Biosciences?

Precision BioSciences (NASDAQ:DTIL) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Precision BioSciences has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.27, indicating that its stock price is 627% less volatile than the broader market.

Bright Minds Biosciences has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Bright Minds Biosciences' return on equity of -20.58% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-72.52%	-32.25%
Bright Minds Biosciences	N/A	-20.58%	-20.25%

In the previous week, Precision BioSciences had 9 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 13 mentions for Precision BioSciences and 4 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.97 beat Precision BioSciences' score of 0.41 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision BioSciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Bright Minds Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Precision BioSciences presently has a consensus target price of $32.25, suggesting a potential upside of 334.05%. Bright Minds Biosciences has a consensus target price of $143.83, suggesting a potential upside of 88.17%. Given Precision BioSciences' higher possible upside, equities analysts clearly believe Precision BioSciences is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Bright Minds Biosciences has lower revenue, but higher earnings than Precision BioSciences. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	5.99	-$45.72M	-$2.80	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A

Summary

Bright Minds Biosciences beats Precision BioSciences on 11 of the 16 factors compared between the two stocks.

How does Precision BioSciences compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Precision BioSciences (NASDAQ:DTIL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Precision BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Candel Therapeutics had 6 more articles in the media than Precision BioSciences. MarketBeat recorded 19 mentions for Candel Therapeutics and 13 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 0.41 beat Candel Therapeutics' score of -0.02 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	2 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Precision BioSciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Candel Therapeutics has higher earnings, but lower revenue than Precision BioSciences. Candel Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Precision BioSciences	$34.26M	5.99	-$45.72M	-$2.80	N/A

Candel Therapeutics currently has a consensus target price of $19.29, suggesting a potential upside of 64.55%. Precision BioSciences has a consensus target price of $32.25, suggesting a potential upside of 334.05%. Given Precision BioSciences' higher probable upside, analysts clearly believe Precision BioSciences is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Candel Therapeutics has a beta of -0.51, meaning that its stock price is 151% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

Candel Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Precision BioSciences' return on equity of -72.52% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-84.70%	-54.37%
Precision BioSciences	-96.73%	-72.52%	-32.25%

Summary

Precision BioSciences beats Candel Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Precision BioSciences compare to Rigel Pharmaceuticals?

Precision BioSciences (NASDAQ:DTIL) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Precision BioSciences presently has a consensus price target of $32.25, indicating a potential upside of 334.05%. Rigel Pharmaceuticals has a consensus price target of $61.50, indicating a potential upside of 44.43%. Given Precision BioSciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Precision BioSciences is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Rigel Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Precision BioSciences has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Rigel Pharmaceuticals has a net margin of 116.30% compared to Precision BioSciences' net margin of -96.73%. Rigel Pharmaceuticals' return on equity of 22.95% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-72.52%	-32.25%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Rigel Pharmaceuticals has higher revenue and earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	5.99	-$45.72M	-$2.80	N/A
Rigel Pharmaceuticals	$294.28M	2.68	$367.02M	$16.32	2.61

In the previous week, Precision BioSciences had 7 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 13 mentions for Precision BioSciences and 6 mentions for Rigel Pharmaceuticals. Precision BioSciences' average media sentiment score of 0.41 beat Rigel Pharmaceuticals' score of 0.38 indicating that Precision BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision BioSciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Rigel Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rigel Pharmaceuticals beats Precision BioSciences on 9 of the 15 factors compared between the two stocks.

Get Precision BioSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DTIL vs. The Competition

Export

Metric	Precision BioSciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$201.49M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-2.65	10.67	269.06	25.28
Price / Sales	5.99	1,262.99	592.57	87.62
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	4.53	16.78	12.91	6.24
Net Income	-$45.72M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-0.80%	1.74%	1.12%	1.07%
1 Month Performance	-13.40%	1.60%	1.79%	1.03%
1 Year Performance	55.77%	56.43%	67.69%	20.77%

Precision BioSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DTIL Precision BioSciences	2.0608 of 5 stars	$7.43 +1.8%	$32.25 +334.1%	+55.7%	$201.49M	$34.26M	N/A	200	Analyst Revision
ACRS Aclaris Therapeutics	2.0704 of 5 stars	$5.92 +0.3%	$11.50 +94.3%	+244.7%	$827.76M	$8.22M	N/A	100	Analyst Revision
CLYM Climb Bio	2.4364 of 5 stars	$13.85 +2.3%	$22.75 +64.3%	+803.7%	$795.54M	N/A	N/A	9	News Coverage Gap Up
DRUG Bright Minds Biosciences	3.1179 of 5 stars	$80.25 -0.7%	$143.83 +79.2%	+92.4%	$780.83M	N/A	N/A	N/A	Earnings Report
CADL Candel Therapeutics	1.9654 of 5 stars	$10.65 +1.4%	$18.57 +74.4%	+84.4%	$780.33M	N/A	N/A	60	Trending News Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DTIL) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Precision BioSciences (DTIL) Competitors

DTIL vs. ACRS, CLYM, DRUG, CADL, and RIGL

How does Precision BioSciences compare to Aclaris Therapeutics?

Summary

How does Precision BioSciences compare to Climb Bio?

Summary

How does Precision BioSciences compare to Bright Minds Biosciences?

Summary

How does Precision BioSciences compare to Candel Therapeutics?

Summary

How does Precision BioSciences compare to Rigel Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL vs. The Competition

Precision BioSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Precision BioSciences (DTIL) Competitors

DTIL vs. ACRS, CLYM, DRUG, CADL, and RIGL

How does Precision BioSciences compare to Aclaris Therapeutics?

Which has better valuation and earnings, ACRS or DTIL?

Do analysts recommend ACRS or DTIL?

Does the media favor ACRS or DTIL?

Which has more volatility & risk, ACRS or DTIL?

Is ACRS or DTIL more profitable?

Do insiders & institutionals hold more shares of ACRS or DTIL?

Summary

How does Precision BioSciences compare to Climb Bio?

Which has preferable earnings and valuation, CLYM or DTIL?

Do analysts prefer CLYM or DTIL?

Which has more risk and volatility, CLYM or DTIL?

Is CLYM or DTIL more profitable?

Do institutionals and insiders have more ownership in CLYM or DTIL?

Does the media prefer CLYM or DTIL?

Summary

How does Precision BioSciences compare to Bright Minds Biosciences?

Do institutionals & insiders hold more shares of DTIL or DRUG?

Which has more volatility & risk, DTIL or DRUG?

Is DTIL or DRUG more profitable?

Does the media favor DTIL or DRUG?

Do analysts recommend DTIL or DRUG?

Which has stronger valuation & earnings, DTIL or DRUG?

Summary

How does Precision BioSciences compare to Candel Therapeutics?

Do institutionals and insiders hold more shares of CADL or DTIL?

Does the media prefer CADL or DTIL?

Which has better earnings & valuation, CADL or DTIL?

Do analysts rate CADL or DTIL?

Which has more risk & volatility, CADL or DTIL?

Is CADL or DTIL more profitable?

Summary

How does Precision BioSciences compare to Rigel Pharmaceuticals?

Do analysts prefer DTIL or RIGL?

Which has more risk & volatility, DTIL or RIGL?

Do institutionals & insiders believe in DTIL or RIGL?

Is DTIL or RIGL more profitable?

Which has preferable earnings and valuation, DTIL or RIGL?

Does the media refer more to DTIL or RIGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL vs. The Competition

Precision BioSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools